Simple Summary Glioblastoma multiforme is one of the hardest-to-treat brain tumors, often
resistant to conventional treatments such as chemotherapy and radiation therapy. Despite …

The growing clinical success of hematopoietic stem/progenitor cell (HSPC) gene therapy
(GT) relies on the development of viral vectors as portable" Trojan horses" for safe and …

Postsurgical treatment of glioblastoma multiforme (GBM) by systemic chemotherapy and
radiotherapy is often inefficient. Tumor cells infiltrating deeply into the brain parenchyma are …

Gliomas are the most prevalent primary malignant brain tumors worldwide, with
glioblastoma (GBM) being the most common and aggressive type. Despite two decades of …

Dendritic cells (DCs) are antigen-presenting myeloid cells that regulate T cell activation,
trafficking and function. Monocyte-derived DCs pulsed with tumor antigens have been tested …

Glioblastoma is the most aggressive primary brain tumor with an unmet need for more
effective therapies. Here, we investigated combination therapies based on L19TNF, an …

Glioblastoma remains as the most common and aggressive malignant brain tumor, standing
with a poor prognosis and treatment prospective. Despite the aggressive standard care …

T cell-based adoptive cell therapy (ACT) has exhibited excellent antitumoral efficacy
exemplified by the clinical breakthrough of chimeric antigen receptor therapy (CAR-T) in …

Adoptive T‐cell transfer (ACT) therapies, including of tumor infiltrating lymphocytes (TILs)
and T cells gene‐modified to express either a T cell receptor (TCR) or a chimeric antigen …

Viruses lacking the capacity to infect mammals exhibit minimal toxicity, good
biocompatibility, and well-defined structures. As self-organized biomolecular assemblies …